Mirati Therapeutics, Inc. (MRTX) EPS Estimated At $-1.26

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Logo
Investors sentiment decreased to 1.73 in 2019 Q2. Its down 0.65, from 2.38 in 2019Q1. It is negative, as 23 investors sold Mirati Therapeutics, Inc. shares while 33 reduced holdings. 47 funds opened positions while 50 raised stakes. 37.63 million shares or 8.46% more from 34.70 million shares in 2019Q1 were reported.
California Public Employees Retirement reported 0.01% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Macquarie Grp Inc has invested 0.04% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Moreover, Cornerstone Advsr has 0% invested in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Perceptive Ltd Liability Com holds 6.85% of its portfolio in Mirati Therapeutics, Inc. (NASDAQ:MRTX) for 2.90M shares. Acuta Cap Partners Ltd Limited Liability Company stated it has 62,500 shares. 12,195 were accumulated by Sei. Financial Bank Of Montreal Can stated it has 0% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Farallon Cap Management Ltd Limited Liability Company stated it has 0.85% of its portfolio in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Sands Mngmt Ltd Liability Com invested in 1.38 million shares. First Mercantile invested 0.01% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Us Bankshares De invested in 224 shares or 0% of the stock. Raymond James & invested 0% of its portfolio in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Advisory Inc holds 13,870 shares. Quantitative Systematic Strategies Llc has 2,635 shares. Dimensional Fund Advisors L P has invested 0% in Mirati Therapeutics, Inc. (NASDAQ:MRTX).

Since July 17, 2019, it had 0 insider buys, and 2 sales for $77.64 million activity. The insider Avoro Capital Advisors LLC sold 62,500 shares worth $6.37 million.

Analysts expect Mirati Therapeutics, Inc. (NASDAQ:MRTX) to report $-1.26 EPS on November, 5.They anticipate $0.41 EPS change or 48.24 % from last quarter’s $-0.85 EPS. After having $-1.26 EPS previously, Mirati Therapeutics, Inc.’s analysts see 0.00 % EPS growth. The stock increased 0.57% or $0.42 during the last trading session, reaching $73.55. About 719,509 shares traded or 38.47% up from the average. Mirati Therapeutics, Inc. (NASDAQ:MRTX) has risen 68.74% since October 7, 2018 and is uptrending. It has outperformed by 68.74% the S&P500.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Ratings Coverage

Among 3 analysts covering Mirati Therapeutics (NASDAQ:MRTX), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Mirati Therapeutics has $10500 highest and $6000 lowest target. $84.75’s average target is 15.23% above currents $73.55 stock price. Mirati Therapeutics had 12 analyst reports since April 17, 2019 according to SRatingsIntel. Cantor Fitzgerald maintained Mirati Therapeutics, Inc. (NASDAQ:MRTX) on Monday, September 9 with “Neutral” rating. The rating was upgraded by Jefferies on Monday, September 9 to “Buy”. The firm has “Neutral” rating given on Wednesday, September 11 by B. Riley & Co.

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company has market cap of $2.80 billion. The company's clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. It currently has negative earnings. The Company’s clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC.

More notable recent Mirati Therapeutics, Inc. (NASDAQ:MRTX) news were published by: Finance.Yahoo.com which released: “Were Hedge Funds Right About Flocking Into Mirati Therapeutics, Inc. (MRTX) ? – Yahoo Finance” on April 29, 2019, also Seekingalpha.com with their article: “Mirati fortunes with KRAS inhibitor tied to Amgen’s – JPMorgan – Seeking Alpha” published on May 14, 2019, Fool.com published: “Here’s Why Mirati Therapeutics, Inc. Is Rising Today – Motley Fool” on June 07, 2018. More interesting news about Mirati Therapeutics, Inc. (NASDAQ:MRTX) were released by: Fool.com and their article: “Winners and Losers of Europe’s Big Cancer Meeting – The Motley Fool” published on October 02, 2019 as well as Prnewswire.com‘s news article titled: “Mirati Therapeutics To Present At Jefferies 2019 Global Healthcare Conference – PRNewswire” with publication date: May 30, 2019.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.